THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 4, 2006--Amgen (Nasdaq:AMGN), the world's largest biotechnology company, today announced plans to report its first quarter financial results on Tuesday, April 18, 2006 after the close of the financial markets. The announcement will be followed by a live conference with the investment community at 2 p.m. Pacific Daylight Time.
Participating in the event from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen's senior management team.
Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. The conference call, including the question and answer session, is expected to last approximately one hour.
The webcast of the conference, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's Web site, www.amgen.com, under Investors. Information regarding presentation times, webcast availability, and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least seven days after the event.
About Amgen
Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.
CONTACT: Amgen, Thousand Oaks Dan Whelan, 805-447-4587 (media) Arvind Sood, 805-447-1060 (investors) SOURCE: Amgen